L19IL2 + L19TNF for Basal Cell Carcinoma

This trial explores a new treatment option for individuals with basal cell carcinoma, a common type of skin cancer, that has worsened despite other treatments. Researchers are testing the effectiveness of a combination of two agents, L19IL2 and L19TNF, injected directly into skin tumors to evaluate their efficacy and safety. This trial may suit those with locally advanced basal cell carcinoma, whose tumors can be injected and who have faced challenges with previous treatments. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group, offering participants a chance to benefit from cutting-edge therapy.

The trial does not specify if you need to stop taking your current medications. However, you cannot be on current topical or systemic chemotherapy or immunotherapy, and you should not be on chronic systemic steroid therapy exceeding 10 mg daily of prednisone equivalent.

Research has shown that treatments using L19IL2 and L19TNF have been tested for skin cancers like basal cell carcinoma. Early results suggest these treatments are generally well-tolerated. In one study, injecting L19IL2/L19TNF directly into melanoma tumors led to positive responses. However, about 48% of patients in other advanced cancer studies experienced serious side effects related to the treatment.

Unlike the standard treatments for basal cell carcinoma, which often involve surgical excision, radiation therapy, or topical medications, L19IL2 + L19TNF offers a novel approach by using targeted immunotherapy. This treatment harnesses the power of cytokines, specifically interleukin-2 (IL2) and tumor necrosis factor (TNF), to directly stimulate the immune response against the tumor. Administered intratumorally, it delivers these potent immune-activating agents directly into the cancerous lesions, potentially increasing effectiveness and minimizing systemic side effects. Researchers are excited because this method could provide a less invasive and more precise alternative for patients with challenging or inoperable tumors.

Research has shown that combining L19IL2 and L19TNF may help treat basal cell carcinoma (BCC). In earlier studies, this combination was tested on patients with non-melanoma skin cancers, including BCC, and demonstrated strong effects against tumors. Similar treatments often achieved success rates over 70%. L19IL2 enhances the immune system to attack cancer cells, while L19TNF directly kills tumor cells. Together, they aim to shrink tumors and halt their growth. These findings suggest that L19IL2/TNF could be effective for BCC patients who haven't responded well to other treatments.¹²³⁴⁶